Ned Pagliarulo
Lead Editor | @NedPagliaruloNed is a lead editor for BioPharma Dive. Before joining Industry Dive, Ned covered economic news for a Japanese newswire and contributed articles on political risk for Global Risk Insights. He has a B.A. from the College at Georgetown University.
2176 articles by Ned Pagliarulo
-
Foundation behind Novo Nordisk to invest $200M in building quantum research ‘powerhouse’
Sept. 21, 2022 -
Merck to resume testing of closely watched HIV drug, but at lower dose
Sept. 20, 2022 -
Back-to-back gene therapy approvals give Bluebird shot at survival
Sept. 19, 2022 -
Bluebird wins FDA approval of gene therapy for rare brain disorder
Sept. 17, 2022 -
Alnylam, Regeneron to advance NASH drug after early signs of potential
Sept. 15, 2022 -
Amgen data supports KRAS cancer drug, but survival benefit remains in question
Sept. 12, 2022 -
How a top FDA official’s words helped push a closely watched ALS drug toward approval
Sept. 9, 2022 -
Relay impresses with early study data for targeted cancer drug
Sept. 8, 2022 -
Sarepta to restart Duchenne drug study after FDA lifts hold
Sept. 6, 2022 -
Sangamo presses ahead with Fabry disease gene therapy
Sept. 1, 2022 -
Amgen says KRAS drug beat chemo in lung cancer study
Aug. 31, 2022 -
‘Treg’ startup Sonoma expands with plans for manufacturing plant
Aug. 24, 2022 -
Pfizer, BioNTech submit omicron booster for FDA clearance
Aug. 22, 2022 -
Pharvaris studies of rare disease drug put on hold by FDA
Aug. 22, 2022 -
With $2.8M gene therapy, Bluebird sets new bar for US drug pricing
Aug. 18, 2022 -
Bluebird gene therapy approved by FDA for rare blood disease
Aug. 17, 2022 -
Moderna, after firing newly hired CFO, finds replacement in PerkinElmer executive
Aug. 17, 2022 -
Novartis bid to repurpose rare disease drug for cancer falls short in third trial
Aug. 15, 2022 -
Amgen’s low tax rates draw attention of top Democratic senator
Aug. 12, 2022 -
Novartis reports deaths of two patients treated with Zolgensma gene therapy
Aug. 11, 2022 -
GSK, Pfizer, Sanofi shares drop amid Zantac litigation concerns
Aug. 11, 2022 -
Bristol Myers claims success in study testing earlier CAR-T use in multiple myeloma
Aug. 10, 2022 -
J&J’s head of R&D departs as pharma’s leadership turns over
Aug. 9, 2022 -
Samantha Truex on biotech hiring, competing for funding and Upstream’s next steps
Aug. 9, 2022 -
Amgen data on KRAS cancer drug disappoints, opening door for rival Mirati
Aug. 8, 2022